Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qinhuang Formula Maintenance Therapy in Elderly DLBCL
ChiCTR2400090671Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2024
- Countries
- 1
01
Overview
Phase 2, randomised trial in diffuse large B-cell lymphoma (DLBCL) comparing Qinhuang Formula maintenance with Placebo maintenance (2 arms). Primary endpoint: 2-year disease-free survival rate. Started Oct 2024; status: recruiting.
02
Drugs
qin huang fang
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400090671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090671.